(12) UnIted States Patent
`(10) Patent N0.:
`US 9,056,120 B2
`
`Zeldis
`(45) Date of Patent:
`*Jun. 16, 2015
`
`USOO9056120B2
`
`(54) METHODS OF TREATING
`MYELODYSPLASTIC SYNDROMES WITH A
`COMBINATION THERAPY USING
`LENALIDOMIDE AND AZACITIDINE
`
`(71) Applicant: Celgene Corporation, Summit, NJ (US)
`
`(72)
`
`Jerome B. Zeldis, Princeton, NJ (US)
`Inventor:
`.
`.
`.
`(73) Ass1gnee: Celgene CorporatIon, Summ1t, NJ (US)
`.
`.
`.
`.
`.
`( * ) Not1ce:
`Subject to any d1scla1mer, the term of thls
`patent is extended or adjusted under 35
`U‘S‘C‘ 154(b)by 0 days‘
`This patent is subject to a terminal dis-
`claimer
`.
`
`(21) APP1~ N05 13/301362
`
`(22)
`
`Filed:
`
`Mar. 13, 2013
`
`(65)
`
`Prior Publication Data
`
`US 2013/0202590 A1
`
`Aug. 8, 2013
`
`_
`_
`Related U-S-Appllcatlon Data
`(60) Continuation of application No. 12/777,765, filed on
`May 11, 2010, now Pat. No. 8,404,716, which is a
`continuation-in-part of application No. 11/985,032,
`filed on Nov. 12, 2007, now Pat. No. 7,863,297, which
`is a continuation of application No. 11/654,550, filed
`on Jan. 16, 2007, now Pat. No. 7,393,863, which is a
`division of application No. 10/411,649, filed on Apr.
`11, 2003, now Pat. No. 7,189,740.
`
`(60) Provisional application No. 60/418,468, filed on Oct.
`15, 2002.
`
`51
`
`I t Cl
`.
`n .
`A61K 31/706
`A61K 31/454
`A61K 39/395
`A61K 45/06
`(52) U'S' Cl'
`CPC ~~~~~~~~~~~~~ A61K 31/706 (2013-01); A61K 31/454
`(2013.01); A61K 45/06 (2013.01); A61K
`39/3955 (2013.01)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(200601)
`
`(58) Field of Classification Search
`USPC ............. 424/1311. 514/43 50 58 274 323
`5
`5
`5
`5 514/575
`.
`.
`.
`See applIcatIon file for complete search h1story.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`3,536,809 A
`3,598,123 A
`3,845,770 A
`3,916,899 A
`4,008,719 A
`4,810,643 A
`4,999,291 A
`5,059,595 A
`5,073,543 A
`5,120,548 A
`
`10/1970 Applezweig
`8/1971 Zaffaroni
`11/1974 Theeuwes et a1.
`11/1975 Theeuwes et a1.
`2/1977 Theeuwes et a1.
`3/1989 Souza
`3/1991 Souza
`10/1991 LeGrazie
`12/1991 Marshall et a1.
`6/1992 McClelland et al.
`
`5,134,127 A
`5,229,496 A
`ggifig‘g; 2
`5:3g5:901 A
`5,391,485 A
`5,393,870 A
`5,528,823 A
`5,580,755 A
`5,591,767 A
`5,593,990 A
`5,629,327 A
`5,635,517 A *
`5,639,476 A
`2,243,355; 2
`,
`,
`5,674,533 A
`5,698,579 A
`5,712,291 A
`5,733,566 A
`5,798,368 A
`5,874,448 A
`5,877,200 A
`5,929,117 A
`5,955,476 A
`
`6,011,050 A
`6,071,948 A
`6,096,757 A
`6,228,879 B1
`6,281,230 B1
`6,316,471 B1
`
`7/1992 Stella et a1.
`74993 Declcy 9t al~
`136133: gawfismfl 6t 31'
`121995 £213,122,:
`2/1995 Deeley et a1.
`2/1995 Deeley etal.
`6/1996 Rudy et al.
`12,1996 Souza
`1/1997 Mohr et al.
`1/1997 D’Amato
`5/1997 D’Amato
`6/1997 Muller et a1.
`6/1997 Oshlack et a1.
`3133;
`filliilet a1.
`1
`/
`is et a .
`10/1997 Santus et al.
`12/1997 Muller
`1/1998 D’Amato
`3/1998 Lewis
`8/1998 Muller et a1.
`2/1999 Muller et a1.
`3/1999 Muller
`7/1999 Muller et 31.
`9/1999 Muller et al.
`
`................. 514/323
`
`1/2000 Muller et al.
`6/2000 D’Amato
`8/2000 BiShOP et aL
`5/2001 Green et a1.
`8/2001 Muller et al.
`11/2001 Muller et a1.
`(Continued)
`
`$50
`
`FOREIGN PATENT DOCUMENTS
`.
`W01 £2232???
`7
`
`lgfiggg
`
`.
`(Contmued)
`OTHER PUBLICATIONS
`
`Raza et al. Thalidomide Produces Transfusion Independence in
`Long-standing Refractory Anemias of Patinets with Myelodysplastic
`Syndromes, Blood, 98(4), 958-965, 2001.*
`fl,
`/
`1
`'
`PCT 'S03 11323 ISR, Sep. 5, 2003. Ce gene Corporation.
`Beazley et al., 1985, “Malignant structure at the confluence of the
`biliary tree: diagnosis and management,” Surg. Annu., 1985, 17:125-
`‘1‘;
`a t
`1 1985 “Pr
`d
`_ d
`_t
`_
`f
`th
`1
`,fi f
`611116
`e a .,
`,
`OPOSC reVlSe
`cr1 Crlfl. 0r
`CC 6.551 ca 1011
`of acute myeloid leukemia. A report ofthe French-American-British
`Cooperative Group,” Ann. Intern. Med. 103(4):620-625.
`Besa, 1992, “Myelodysplastic syndromes (refractory anemia).Aper-
`spective ofthe biologic, clinical, and therapeutic issues,”Med. Clin.
`NorthAm. 76(3):599-617.
`_
`_
`_
`3353 et 31-, 1990, 76(5111313' 111334
`Bowen etal., 1991, “Thetreatrnentofanaemlalnthemyelodysplastlc
`syndromes with recombinant human erythropoietin,” Br.
`J.
`Haematol. 77(3):419-423.
`.
`(Continued)
`
`Primary Examiner 7 Michael G Hartley
`Assistant Examiner 7 Jagadishwar Samala
`(74) Attorney, Agent, or Firm 7 Jones Day
`
`ABSTRACT
`(57)
`Methods of treating, preventing and/or managing myelodys-
`plastic syndromes are disclosed. Specific methods encom-
`pass the administrations of 3—(4—amino—l—oxo—1,3—dihydro—
`isoindol—2—yl)—piperidin—2,6—dione
`in
`combination with
`5-azacytidine.
`
`53 Claims, No Drawings
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 1
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 1
`
`

`

`US 9,056,120 B2
`
`Page 2
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`6,335,349 B1
`6,380,239 B1
`6,395,754 B1
`6,403,613 B1
`6,420,414 B1
`6,432,924 B1
`6,458,810 B1
`6,469,045 B1
`6,476,052 B1
`6,518,298 B2
`6,673,828 B1
`6,887,855 B2 *
`6,890,547 B1
`6,943,249 B2
`7,078,518 B2
`01/0021380 A1
`01/0026807 A1
`01/0056114 A1
`02/0035090 A1
`02/0045643 A1
`
`1/2002 Muller et a1.
`4/2002 Muller et a1.
`5/2002 Muller et a1.
`6/2002 Man et al.
`7/2002 D’Amato
`8/2002 Nyce
`10/2002 Muller et a1.
`10/2002 D’Amato
`11/2002 Muller et a1.
`2/2003 Green et a1.
`1/2004 Green et a1.
`5/2005 Ionescu et a1.
`5/2005 Takada et a1.
`9/2005 Ionescu et al.
`Ionescu et a1.
`7/2006
`9/2001 Pluenneke
`10/2001 Watts
`12/2001 D’Amato
`3/2002
`Zeldis et a1.
`4/2002
`Muller et a1.
`
`.................. 514/43
`
`02/0051820 A1
`02/0052398 A1
`02/0054899 A1
`02/0061923 A1
`02/0161023 A1
`02/0173658 A1
`02/0183360 A1
`3
`ggéggzggég 1:1
`03/0045552 A1
`03/0049311 A1
`03/0069428 A1
`03/0096841 Al
`03/0104053 A1
`03/0104062 A1
`03/0139451 A1
`03/0144325 A1
`3333: :1
`83%;;(1)32: :i
`03/0235909 A1
`04/0029832 A1
`04/0077685 A1
`04/0077686 A1
`04/0087546 A1
`04/0091455 A1
`04/0122052 A1
`04/0 1 5 2632 A1
`04/0162263 A1
`05/0272675 A1
`06/0247189 A1
`07/0270374 A1
`08/0057086 A1
`09/0286752 A1
`10/0278779 A1
`11/0172273 A1
`
`5/2002 Shell et 31'
`o
`5/2002 D’Amat
`5/2002 Zeldis
`5/2002 D’Amato
`10/2002 D’Amato
`11/2002 Muller et 31.
`12/2002 Muller et a1.
`e eta .
`Z588;
`13511111“ 311'
`3/2003 Robarge et al.
`3/2003 McAllister et al.
`4/2003 Muller et al.
`5/2003
`Robarge et al.
`6/2003
`Guslcr ct al.
`6/2003
`Berner et al.
`7/2003 Shah et al.
`7/2003 Muller et 3L
`.333 3:3:
`,
`#3388; 211%;
`12/2003 Hariri et al.
`2/2004 Zeldis
`4/2004 Figg et al.
`4/2004 Dannenberg et 31.
`5/2004 Zeldis
`5/2004 Zeldis
`6/2004 Muller et al.
`8/2004 Feingold
`8/2004 Sands et a1.
`12/2005
`Ionescu et al.
`11/2006
`Ionescu et al.
`11/2007
`Gallop
`Etter
`3/2008
`11/2009
`Etter et a1.
`11/2010
`Zeldis
`7/2011
`Zeldis
`
`FOREIGN PATENT DOCUMENTS
`
`MNNNNNNNNNNNNtQNNNNNNNNNNNNNNNNNNNNNNNNNNNN
`
`
`
`WO 98/03502
`W0
`WO 98/54170
`W0
`WO 01/87306
`W0
`WO'Ol/87307
`W0
`WO 01/87307
`W0
`WO 02/15926
`WO
`WO 02/059106
`W0
`W0 03/097040
`W0
`W0 03/097052
`W0
`WC 2004/03 5064
`W0
`W0 W0 2005/1 10085
`W0 W0 2005/110408
`W0
`WO 2006/063111
`W0
`WO 2008/027049
`
`1/1998
`12/1998
`11/2001
`11/2001
`”/2001
`2/2002
`8/2002
`11/2003
`“/2003
`4/2004
`11 /2005
`11/2005
`6/2006
`3/2008
`
`W0
`W0
`W0
`
`3/2008
`WO 2008/028193
`4/2009
`WO 2009/052287
`5/2009
`WO 2009/058394
`OTHER PUBLICATIONS
`
`: friend or foe to cancer vac-
`
`CaItensen, 1995, Drug Stability: Principles & Practice, 2nd ed.,
`Marcel Dekker, New York, NY pp. 379-3 80.
`Corral et al., 1999, Ann. Rheum. Dis. 58(Supp. I):1107-1113.
`Costa et a1., 1998, Blood 92(10:suppl. I):235b, Abstract #4007.
`D’Amato et al., 1994, “Thalidoide is an inhibitor of angiogenesis.”
`PNAS USA 91(9):4082-4085.
`Dexter, 1989, “Haemopoietic growth factors,” Br. Med. Bull.
`45(2):337-349.
`Dexter, 1987, “Growth factors involved in haemopoiesis.” J. Cell.
`Sci 88(Pt1):1-6.
`Dredge et a1., 2002, “Novel thalidomide analogues display anti-
`angiogenic activity independently of immunomodulatory effects.”
`Br- J- Cancer 87(10):1166-1172.
`Ehrenpreis et a1., 1999, “Thalidomide therapy for patients with
`refractory Crohn’s disease: an open-label trial,” Gastroenterology
`117(6):1271-1277.
`Emens et al.. 2001. “Chemolhera
`-
`»
`-
`W
`cmcs? Curr. Opin. Mol. Ther. 3(1):77-84.
`Golde et a1., 1988, “Hormones that stimulate the growth of blood
`cells,” Sci Am. 259(0162-71
`Goldberg et a1., 1990, “Survey of exposure to genotoxic agents in
`primary myelodysplastic syndrome: correlation with chromosome
`patterns and data on patients without hematological disease,” Cancer
`R .50 21 :6876-6881.
`Ges
`b(
`)
`1 1997 “I
`-
`1
`-
`f
`1
`-
`reen erg-et a .,
`,
`nternatlona scor1ng system or eva uat1ng
`prognos1s 1n myelodysplast1c syndromes," Blood 89(6):2079-2088.
`Gupta et a1., 2001, “Adherences of multiple myeloma cells to bone
`marrow stromal cells upregulates vascular endothelial grth factor
`secretion: therapeutic applications,” Leukemia 15 : 1950-1961 .
`Handman et a1., 1979, “Stimulation by granulocyte-macrophage
`colony-stimulating factor or Leishmania tropica killing by macroph-
`1
`12.2w
`.
`.
`.
`.
`Harr1s et a1., 1999, World Health Organlzatlon c1ass1ficat10n of
`neoplastic diseases ofthe hematopoietic and lymphoid tissues: report
`ofthe Clinical Advisory Committee meeting-Airlie House, Virginia,
`Nov. 1997,” J Clin. Oncol. 17(12):3835-3849.
`.
`.
`Hellsm’m et 31“: 199.0: 76.(SuPP' 012793
`Koch, 1985, Thalldomlde and congeners as ant1-1nflammatory
`agents.” Prog. Med. Chem. 22:165-242.
`Kronfa 2000~ 31000] 9601 Part 911683-
`Kurland et a1., 1979, “Induction of prostaglandin E synthesis in
`normal and neoplastic macrophages: role for colony-stimulating fac-
`tor(s) distinct from effects on myeloid progenitor cell proliferation.”
`Proc. Natl. Acad Sci. USA 76(5):2326-2330.
`Lentzsch et a1., 2003, “Immunomodulatory analogs of thalidomide
`inhibit growth ofHs Sultan cells and angiogenesis in vivo,” Leukemia
`17(1);41-44.
`List, 2002, ASH Abstract #521.
`Marriott et al., 2001, “Immunotherapeutic and antitumour potential
`of thalidomide analogues,” Expert Opin. Biol. Ther. 1(4):675 -682.
`McCann, 1999, Drug Topics pp. 41-42 (Jun. 21, 1999).
`The MerckMahual, 1999, 17”1 ed., pp. 953-955.
`Metcalf, 1985, “The granulocyte-macrophage colony-stimulating
`factors,” Science 229(4708):16-22.
`Moller et a1., 1997, “Inhibition ofIL-12 production by thalidomide.”
`J. Immunol. 159(10):5157-5161.
`Moore, 1991. “The clinical use of colony stimulating factors,” Amt.
`Rev. Immunol. 9:159-191.
`Moore et a1., 1980, “Production of lymphocyte-activating factor
`(Interleukin 1) by macrophages activated with colony-stimulating
`,,
`factors,
`J. Immunol. 125(3):1302-1305.
`Muller et a1., 1999, “Amino-substituted thalidomide analogs: potent
`inhibitors of TNF-alpha production,” Bioorg. Med Chem. Lett.
`900116254630.
`Muller et al.. 1998. “Thalidomide analogs and PDE4 inhibition.”
`Bioorg. Med. Chem. Lett. 8(19):2669-2674.
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 2
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 2
`
`

`

`US 9,056,120 B2
`Page 3
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Muller et al., 1996, “Structural modifications ofthalidomide produce
`analogs with enhanced tumor necrosis factor inhibitory activity," J.
`r\/[ed Chem. 39(17):3238-3240.
`Munshi et al., 1999, Blood 94(10 part 1):578a.
`Ogawa, 1989, “Hemopoietic stem cells: stochastic differentiation
`and humoral control of proliferation,” Environ. Health Perspect.
`80: 199-207.
`Payvandi et al., 2003, ASCO Abstract #992.
`Penichet et al., 2001, “Antibody-cytokine fusion proteins for the
`therapy of cancer,” J. Immunol. Methods. 248(1-2):91-101.
`Physicians’ Desk Reference, 2002, 56the ed. pp. 582—592, 1154—
`1158,1755-1760.
`Raza et al., 2001, “Thalidomide Produces Transfusion Independence
`in Long-standing Refractory Anemias
`of Patients with
`Myelodysplastic Syndromes,” Blood 98(4):958-965.
`Schrader et al., 1981, “The persisting (P) cell: histamine content,
`regulation by a T cell-derived factor, origin from a bone marrow
`precursor, and relationship to mast cells,” Proc. Natl. Acad. Sci. USA
`78(1):323-327.
`Schuster et al., 1990, Blood 76(Supp. 1):318a.
`Singhal et al., 1999, “Antitumor activity of thalidomide in refractory
`multiple myeloma,” N. Engl. J. Med. 341(21):]565-1571.
`Stanley et al., 1976, “Factors regulating macrophage production and
`growth:
`identity of colony—stimulating factor and macrophage
`growth factor,” J. Exp. Med. 143(3):631-647.
`Tabbara et al., 1991, “Hematopoietic growth factors,” Anticancer
`Res. 11(1):81-90.
`Vadas et al., 1983, “Eosinophil activation by colony-stimulating fac-
`tor in man: metabolic effects and analysis by flow cytometry,” Blood
`61(6):1232-1241.
`Vadas et al., 1983, “Activation of antibody—dependent cell—mediated
`cytotoxicity of human neutrophils and eosinophils by separate
`colony-stimulating factors,” J. Immunol. 130(2):795-799.
`Vasiliauskas et al., 1999, “An open-label pilot study of low-dose
`thalidomide in chronically active, steroid-dependent Crohn’s dis-
`ease," Gastroenterology 117(6): 1278-1287.
`Weisbart et al., 1986, “Biosynthetic human GM-CSF modulates the
`number and affinity of neutrophil f-Met-Leu-Phe receptors.” J
`Immunol. 137(11):3584-3587.
`Wolff, ed.. 1995, Burger ’s Medicinal Chemistry and Drug Discov—
`ery, 5th ed, pp. 172-178, 949-982.
`Goerner et al., 2002, Morbidity and mortality of chronic GVHD after
`hematopoietic stem cell transplantation from HLA-identical siblings
`or patients with aplastic or refractory anemias, Biology ofBlood and
`ri/[arrow Transplantation (Abstract only) 8(1):47-56, accessed from
`Database STN/CAPLUS, Fred Hutchinson Cancer Research Center
`and the University of Washington, Seattle, WA, Accession No.
`200221195127.
`{urzrock, 2002, “Myelodysplastic syndrome overview,” Seminars in
`Hematology (Abstract only) (Suppl. 2) 39(3).
`N. Ake Jonnson, 1972. “Chemical, Structure and Teratogenic Prop—
`erties,” Acta Pharm., pp. 521 -542.
`Bellamy et al., 2001, “Vascular endothelial cell growth factor is an
`autocrine promoter of abnormal localized immature myeloid precur-
`sors and leukemia progenitor formation in myelodysplastic syn-
`dromes," Blood 97: 1427-1434.
`3ennett et al., 1982, “Proposals for the classification of the
`myelodysplastic syndromes,” Br. J. Haematol. 51:189-199.
`3umm et al., 2003, “Emergences of clonal cytogenic abnormalities in
`pH-cells in some CML patients in cytogenic remission to imatinib but
`restoration of polyclonal hematopoiesis in the majority.” Blood
`101:1941-1949.
`Cancer Therapy Evaluation Program, 1998, “Common toxicity cri-
`teria,” Version 2.0, Bethesda, MD: Division of Cancer Treatment and
`Diagnosis. National Institutes of Health. Mar. 1998. (Accessed Jan.
`18, 2005, at http://ctep.cancergov/reporting/ctc.html.).
`Cheson et al., 2000. “Report of an international working group to
`standardize response criteria for myelodysplastic syndromes,” Blood
`96:3671-3674.
`
`
`
`Claessens et al., 2002, “In vitro proliferation and differentiation of
`erythroid progenitors from patients with myelodysplastic syn-
`dromes: evidence for Fas-dependent apoptosis,” Blood 99: 1594-
`1601.
`Corral et al., 1999, “Differential cytokine modulation and T cell
`activation by two distinct classes of thalidomide analogues that are
`potent inhibitors of TNF-alpha,” J. Irnrnunol. 163:380-3 86.
`Davies et al., 2001, “Thalidomide and immunomodulatory deriva—
`tives augment natural killer cell cytotoxicity in multiple myeloma,”
`Blood 98:210-216.
`Deeg et al., 2002, “Soluble TNF receptor fusion protein (etanercept)
`for the treatment of myelodysplastic syndrome: a pilot study,” Leu-
`kemia 16:162-164.
`Gersuk et al., 1996, “Fas (CD95) receptor and Fas-ligand expression
`in bone marrow cells from patients with myelodysplastic syndrome.”
`Blood 88(3): 1 122-1 123.
`Goldberg et al., 2003, “Myelodysplastic subclones in chronic
`myeloid leukemia:
`implications for imatinib mesylate therapy.”
`Blood 1012781.
`He, W., et al., 1993, Abstract of papers, 206th American Chemical
`Society, Chicago, IL; Med. Chem., paper 216.
`Hellstrom-Lindberg et al., 1997, “Erythroid response to treatment
`with G-CSF plus erythropoietin for the anaemia of patients with
`myelodysplastic syndromes: proposal for a predictive model,” Br. J.
`Haematol. 99:344-351.
`Jaffe et al., eds., 2001, “World Health Organization classification of
`tumours: pathology and genetics of tumours of haematopoietic and
`lymphoid tissues,” Lyon, France: IARC Press pp. 61-74.
`Kaplan et al., 1958, “Nonparametric estimation from incomplete
`observations,” J. Am. Stat. Assoc. 53:457-481.
`Kitagawa et al., 1997, “Overexpression of tumor necrosis factor
`(TNF)-ot and interferon (INF)-y by bone marrow cells from patients
`with myelodysplastic syndromes.” Leukemia 11:2049-2054.
`List et al., 2005, “Efficacy of Lenalidomide in myelodysplastic syn-
`dromes,” N. Engl. J. Med. 352(6):549-557.
`List et al., 2004, “Myelodysplastic syndromes,” Wintrobe’s Clinical
`Hematology, 11th ed., Philadelphia: Lippincott Williams & Wilkins
`pp. 2207-2234.
`List et al., 2004, “Vascular endothelial growth factor receptor-l and
`receptor-2 initiate a phosphatidylinositide 3-kinase-dependent
`clonogenic response in acute myeloid leukemia cells,” Exp. Hematol.
`32:526-535.
`Maciejewski et al., 2002. “A pilot study of the recombinant soluble
`human tumour necrosis factor receptor (p75)-Fc fusion protein in
`patients with myelodysplastic syndrome,” Br. J. Haematol. 117:119.
`Moreira et al., 1993, “Thalidomide exerts its inhibitory action on
`tumor necrosis factor alpha by enhancing mRNA degradation,” J.
`Exp. Med. 177:1675—1680.
`in CD34+
`Peddie
`et
`al.,
`1997,
`“Oxidative DNA damage
`myelodysplastic cells in associated with intracellular redox changes
`and elevated plasma tumor necrosis factor-0t concentration,” Br. J.
`Haematol. 99:625-631.
`Rajapaksa et al., 1996, Altered oncoprotein expression and apoptosis
`in myelodysplastic syndrome marrow cells,: Blood 88:4275-4287.
`Raza et al., 1995. “Apoptosis in bone marrow biopsy samples involv-
`ing stromal
`and hematopoietic
`cells
`in 50 patients with
`myelodysplastic syndromes,” Blood 86:268-276.
`Richardson et al., 2002. “Immunmodulatory drug CC-5013 over-
`comes drug resistance and is well tolerated in patients with relapsed
`multiple myeloma,” Blood 100:3063-3067.
`Rose et al., 1995, “The use of r-HuEpo in the treatment anaemia
`related to myelodysplasia (MDS),” Br. J. Haematol. 89:831-837.
`Tauro et al., 2002. “Functional disturbance of marrow stromal
`microenvironment in the myelodysplastic syndromes,” Leukemia
`16:785-790.
`“Binding of thalidomide to alphal-acid
`1996,
`l'urk et al.,
`glycoprotein may be involved in its inhibition of tumor necrosis
`factor alpha production,” PNAS USA 93:7552-7556.
`Hideshima et a1. 2000, “Thalidomide and its analogs overcome drug
`resistance of human multiple myeloma cells to conventional
`therapy,” Blood 96(9):2943-2950.
`Baker, AF; Bellamy, WT; Glinsmann-Gibson, B; Heaton, R.; Buresh,
`A.; Grogan, TM; List, AF; “Biological response to Thalidomide in
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 3
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 3
`
`

`

`US 9,056,120 B2
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`
`
`{emitting Patients with Myelodysplastic Syndrome (MDS) Evi-
`dence for Induction of Neoplastic Vascular Endothelial Growth Fac-
`tor (VEGF) Resistance” Blood 2001; 98(11):353a-4a, Abstract
`#1490.
`3011rs,V; Franzoso, G; Brown, K.; Park, S.; Azarenko, V.; Tomita-
`Yamaguchi, M.; Kelly, K.; Siebenilist, U.; “Lymphocyte Activiation
`and the Family of NF-kB Transcription Facor Complexes.” Corrent
`Topics in Microbiology and Immunology 1992; 182: 411-20.
`dist, AF; “Pharmacological Differentiation and Anti-Apoptic
`Therapy in Myelodysplastic Syndromes; Forum Trends in Experi-
`mental and Clinical Medicine,” 9:35-45,1999.
`dist, AF; Brasfield, F.; Heaton, R.; Glinsmann-Gibson, B.; Crook, L.;
`Taetle, R.; Capizzi, R.; Stimulation of Hematopoiesis by Amifostine
`in Paitentswith Myelodysplattic Syndrom. Blood 1997; 90(9): 3364-
`9.
`sist, AF; “New Approaches to the Treatment of Myelodysplastia,"
`The ONcologist 2002; 7 Suppl. 1:39-49.
`Thomas. D.A,, Aguayo. A., Estey, F., Albitar, M., O’Brien, S., Giles,
`3.1, Beran, M., Cortes, J., Zeldis, J., Keating, M.J., Barlogie, B.,
`{antarjian, H.M., Thalidomide as anti-angiogenesis therapy (rx) in
`refractory or relapsed leukemia. Abstract #2269, American Society
`of Hematology, Dec. 3-7, 1999.
`Raza, A., Lisak. L., Andrews, C., Little, L., Muzammil, M., Alvi, S.,
`Mazzoran, L., Zorat, F., Akber, A., Ekbal, M., Razvi, S., Venugopal,
`)., Thalidomide produces transfusion independence in patients with
`long-standing refractory anemias and myelodysplastic syndromes
`(MDS). Abstract #2935, Amer. Soc. of Hematology, Dec. 3-7, 1999.
`Raza, A., Lisak, L., Andrews, C., Little, L., Zorat, F., Shetty, V., Alvi,
`S., Mundle, S., Allampallam, K., Durandt, M., Ekbal, M., Muzammil,
`M., Encouraging improvement
`in cytopenias of patients with
`myelodysplastic syndromes (MDS) with thalidomide. Abstract #1 11,
`Amer. Soc. of Clinical Oncology, May 20-23, 2000.
`Raza, A., Lisak, L., Little, L., Dean, L., Gezer, S., Venugopal, V.,
`Summary and future direction of anti-tumor necrosis factor (TNF)
`therapies in myelodysplastie syndromes (MDS). Abstract #2700,
`American Society of Hematology, May 12-17, 2001.
`Mundle, S., Zorat, F., Shetty, V., Allampallam, K., Alvi, S., Lisak, L.,
`Little, L., Dean, L., Nascimben, F., Ekbal, M., Durandt, M.,
`Broderick. E., Venugopal,
`P., Raza, A., Thalidomide
`in
`myelodysplasia. Abstract #626, American Society of Hematology,
`Dec. 1-5, 2000.
`Raza, A., Lisak, L., Little, L., Ekbal, M., Durandt, M., Ali, E,
`Nascimben, F., Tareen, M., Venugopal, P., Thalidomide as a single
`agent or in combination with topotecan, pentoxifylline and/or enbrel
`in myelodysplastic syndromes (MDS). Abstract #627, American
`Society of Hematology, Dec. 1-5, 2000.
`Estey, E., Albitar, M., Cortes, J., Giles, E, Thomas, D., Koller, C.,
`Beran, M., Kantarjian, H., Addition of thalidomide(T) to chemo-
`therapy did not increase remission rate in poor prognosis AML/MDS
`Abstract #1394, American Society of Hematology, Dec. 1-5, 2000.
`Alvi, S., Henderson, B., Shaher, A., Dangerfield, B., Broderick, E.,
`Jafri, N., Tareen, M., Durandt, M., Galili, N., Borok, R.Z., Ra7a, A.,
`Determination of clonality in stromal and parenchyrnal cells pre and
`post
`thalidomide treatment
`in myelodysplasia. Abstract #1536,
`American Society of Hematology, Dec. 1-5, 2000.
`Alvi, S., Shaher, A., Henderson, B., Dar, S., Zorat, F., Broderick E.,
`disak, L., Durandt, M., Reddy, P., Mundle, S., Galili, N., Borok, R.Z.,
`{aza, A., Improved growth of stromal cells in long term bone marrow
`cultures (LTBMC) of myelodysplastic syndrome (MDS) patients
`treated with thalidomide. Abstract #1547, American Society of
`Iematology, Dec. 1-5, 2000.
`)ourado, C. Mc., Seixas-Silva Jr., J.A., Besa, E.C., Response to
`thalidomide in 9 patients with myelodysplastic syndromes: A prom-
`ising treatment for early or post-chemotherapy in late forms of MDS.
`Abstract #4855, American Society of Hematology, Dec. 1-5, 2000.
`sisak, L.A., Little, L., Dean, L., Ekbal, M., Durandt, M., Hussain, M.,
`{aistha, V., Raza, A., Delayed responses to thalidomide in patients
`with myelodysplastic syndromes. Abstract #4861, American Society
`of Hematology, Dec. 1-5, 2000.
`
`
`
`Anders, O., Plath, F., Emmrich, J., Freund, M., Complete remission
`or
`therapy-resistant
`angiodysplasia
`of
`the
`stomach
`in
`myelodysplastic syndrome following thalidomide. Abstract #3820,
`American Society of Hematology, Dec. 7-11, 2001.
`Alvi, S., Shaher, A., Shaikh, M., Anthwal, S., Siddiqi, F.,Akhtar, A.,
`Ashraf, H., Meager, R., Mundle, S., Shetty, V., Goldberg, C., Galili,
`N., Borok, R.Z., Rasa, A., MDS patients with hematological response
`to thalidomide show enhanced in vitro growth potential. Abstract
`#1482, American Society of Hematology, Dec. 7-11, 2001.
`Alvi, S., Shaikh, M., Anthwal, S., Shaher, A., Tamoseviciene, D.,
`Novick, A., Reddy, P., Allampallam, K., Hsu, VV.T., Galili, N., Borok,
`R.Z., Rasa, A., Cytogenetic and clonal profile of myelodysplastic
`syndromes (MDS) patients treated with thalidomide. Abstract #1483,
`American Society of Hematology, Dec. 7-11, 2001.
`Alvi, S., Anthwal, S., Shaikh, M., Shaher, A., Shetty, V., Mundle, S.,
`Reddy P., Allampallam, K., Bi, S., Zorat, F., Tamosveiciene, D.,
`Rasila, K., Meagher, R., Westbrook, C., Galili, N., Gezer, S.,
`Venugopal, P., Borok, R.Z., Raza, A., Thalidomide significantly aug-
`ments proliferation and cytokine secretion to bone marrow cultures
`established from myelodysplastic
`syndrome (MDS) patients.
`Abstract #1484, American Society of Hematology, Dec. 7-11, 2001.
`Baker, A.F., Bellamy, W.T., Glinsmann-Gibson, B.J., Heaton, R.,
`Buresh, A., Grogan, T.M., List, A.F., Biological
`response to
`thalidomide in remitting patients with myelodysplastic syndrome
`(MDS): Evidence for induction of neoplastic vascular endothelial
`growth factor (VEGF) resistance. Abstract #1490, American Society
`of Hematology, Dec. 7-11, 2001.
`Musto, P, Falcone, A., Bodeni77a, C, Sanpaolo, G., Matera, R.,
`Biseeglia, M., Carella, A.M., Thalidomide (THAL) significantly
`improves anemia in selected transfusion-dependent patients with
`myelodysplastic syndromes (MDS): relationship to serum and mar-
`row levels of angiogenetic growth factors (AGF). Abstract #2606,
`American Society of Hematology, Dec. 7-11, 2001.
`Fabbri, A., Biscardi, M., Innocenti, F., Balestri, G., Gavazzi, S.,
`Bellesi, G., Gro ssi, A., Thalidomide in combination with Amifostine
`in the treatment of MDS: evaluation of clinical and laboratory, find-
`ings. Abstract #4819, American Society of Hematology, Dec. 7-11,
`2001.
`Raza, A., Lisak, L., Dun, D., Dean, L., Fantroy, L., Ali, E., Gezer, S.,
`Hsu, W—T., Goldberg, C., Loew, J., Venugopal, P., Combination of
`thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone
`(PCD) in patients with myelodysplastic syndromes (MDS). Abstract
`#4830, American Society of Hematology, Dec. 7-11, 2001.
`Raza, A., Dutt, D., Lisak, L., Dean, L., Fantroy, L., Gezer, S., Ali, E.,
`Goldberg, C., Loew, J., Hsu, W-T., Venugopal, P., Combination of
`thalidomide and enbrel
`for
`the
`treatment of patients with
`myelodysplastic syndromes (MDS). Abstract #4831 . American Soci—
`ety of Hematology, Dec. 7-11, 2001.
`Shetty, V., Allampallam, K., Hussaini, S., Townsend, W., Dun, D.,
`Mundle, S., Alvi, S., Reddy, P.L., Ashraf, H., Galili, N., Saberwal,
`G.S., Anthwal, S., Shaikh, M.W., Heidelberg, A., Lisak, L., Gezer, S.,
`Venugopal, P., Raza, A., Effects of anti-cytokine agents on apoptosis,
`proliferation, monocyte/macrophage number, microvessel density
`and cytokines following two successive clinical trials in 57 patients
`with myelodysplastic syndromes (MDS). Abstract #4837. American
`Society of Hematology, Dec. 7-11, 2001.
`Barlogie, B., Desikan, R., Munshi, N., Siegel, D., Mehta, J., Singhal,
`S., Anaissie, E., Single Course D.T. Pace Anti-Angiochemotherapy
`Effects CR in Plasma Cell Leukemia and Fulminant Multiple
`Myeloma (MM) Abstract #4180. American Society of Hematology,
`Dec. 4-9, 1998.
`Hideshima, T., Chauhan, D., Shima,Y., Noopur, R., Davies, F.E., Tai,
`Y., Treon, S.P., Lin, B.K., Schlossman, R.L., Richardson, P.G.,
`Gupta, D., Muller, G.W., Stirling, D.E., Anderson, K.C., Thalidome
`('l'l-IAL) and its Analogs Overcome Drug Resistance of Human Mul-
`tiple Myeloma (MM) Cells to Conventional Therapy. Abstract #1313.
`American Society of Hematology, Dec. 1—5, 2000.
`Payvandi, F., Wu, L., Gupta, D,, Hideshima, T., Haley, M., Muller, G.,
`Chen, R., Anderson, K.C., Stirling, D., Effects of a Thalidomide
`Analog on Binding Activity or Transcription Factors and Cell Cycle
`Progression of Multiple Myeloma Cell Lines. Abstract #2487.
`American Society of Hematology, Dec. 1-5, 2000.
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 4
`
`DR. REDDY’S LABS., INC. EX. 1001 PAGE 4
`
`

`

`US 9,056,120 B2
`
`Page 5
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`
`
`
`
`
`Davies, FE, Raje, N., Hideshima, '1'., Lentzsch, S., Young. G., 'l'ai, Y.,
`Lin. B.K., Podar, K., Chauhan, D., Treon, S.P., Gupta, D., Mitsiades,
`C., Mitsiades. N., Hayashi, T., Richardson, P.G., Schlossman, R.L.,
`Muller, G.W., Stirling, D. I., Anderson, K.C., Thalidomide (THAL)
`and Immunomodulatory Derivatives (IMiDS) Augrnent Natural
`Killer (NK) Cell Cytotocixity in Multiple Myeloma (MM). Abstract
`#3617. American Society of Hematology, Dec. 1-5, 2000.
`Hideshima, T., Chauhan, D., Castro, A., Hayashi, T., Mitsiades, C.,
`Mitsiades, N., Akiyama, M., Richardson, P.G., Schlossman, R.L.,
`Adams, J., Anderson, K.C., NF-KB as a Therapeutic Target in Mul-
`tiple Myeloma (MM). Abstract #1581. American Society of Hema—
`tology, Dec. 7-11, 2001.
`sentsch, S., Rogers, M., Leblanc, R., Birsner, A., Shah, J., Anderson
`{., D7Amato R., 3-Amino-Phthalimido-Glutarimide (S-3APG)
`nhibits Angiogenesis and Growth in Drug Resistant Multiple
`Myeloma (MM) in vivo. Abstract #1976, American Society of Hema-
`tology, Dec. 7-11, 2001.
`)ark,Y., Kim, S.A., Kim, C.J., Chung, J.H., Mechanism or the Effect
`ofThalidomide on Human Multiple Myeloma Cells, Abstract #2685.
`American Society of Clinical Oncology, May 12-17, 20 1.
`)ayvandi, F., Wu, L., Hale M., Gupta, D., Zhang, L., Schafer, P.,
`Vluller, G.W., Chen, R., Anderson, K.C., Stirling, D., '1' ralidomide
`Analogs IMiDS Inhibit Expression of Cyclooxygenase-2 in Multiple
`Myeloma Cell Line and LPS Stimulated PBMCs. Abstract #2689,
`American Society of Hematology, Dec. 7-11, 2001.
`VIitsiades, N., Mitsiades, C., Poulaki, V., Akiyama, M., Tai,Y., Lin,
`I, Hayashi, T., Catley, L., Hideshima, T., Chauhan, D., Treon, S.P.,
`Anderson, K.C., Apoptotic Signaling Induced by Immunomodula-
`tory Thalidomide Analogs (Imids) in Human Multiple Myeloma
`Cells: Therapeutic Implications. Abstract #3224. American Society
`of Hematology, Dec. 7—1 1, 2001.
`fichardson, P.G., Schlossman, R.L., Hideshima, T., Davies, F.,
`seblanc, R., Catley, L., Doss, D., Kelly, K.A., Mckenney, M.,
`VIechlowiez, J., Freeman, A,. Deocampo, R., Rich, R., Ryoo, J.,
`Chauhan, D., Munshi, N., Weller, E., Zeldis, J., Anderson, K.C., A
`)hase 1 Study ofOral CC5013, an Immunomodulatory Thalidomide
`(Thal) Derivative, in Patients With Relapsed and Refractory Multiple
`Myeloma (MM). Abstract #3225. American Society of Hematology,
`Dec. 7-11, 2001.
`Zangari, M. Tricot, G., Zeldis, J., Eddlemon, P., Saghafifar, F.,
`3arlogie, B., Results of Phase I Study of CC5013, for the Treatment
`of Multiple Myeloma (MM) Patients Who Replase After High Dose
`Chemotherapy (HDCT). Abstract #3226. American Society of
`{ematology, Dec. 7-11. 2001.
`Thomas, D.A. et al., “The revitalization of thalidomide,” Annals of
`Oncologa Jul. 2001, 12(7):885-886.
`3ain, Barbara J.. “The Relationship between the Myelodysplastic
`Syndromes and the Myeloproliferative Disorders,” Leukemia &
`Lymphoma, 1999, 34(5-6):443-449.
`Melchert, Magda, et al., “The thalidomide saga,” The International
`Journal ofBiochemistry & Cell Biology. Jul. 2007, 39:1489-1499.
`Search Report
`in corresponding ARIPO Appl. No. AP/P/2006/
`003799 dated Mar. 3, 2009.
`Sorbera, L. eta1., “CC-5013. Treatment of Multiple Myeloma, Treat-
`ment of Melanoma, Treatment of Myelodysplastic Syndrome,
`Angiogenesis Inhibitor, TNF-or Production Inhibitor," Drugs of
`Future, 2003, 28(5):425-431.
`List, Alan F. et al., “High Erythropoietic Remitting Activity of the
`Immunomodulatory Thalidomide Analog, CC5013, in Patients with
`Myelodysplastic Syndrome (MDS),” Blood, 2002, 100(11):96a
`Abstract #353.
`List, Alan F. et al., “Efficacy and Safety of CC5013 for Treatment of
`Anemia in Patients with Myelodysplastic Syndromes (MDS),"
`Blood, 2003, 102(1 1):184a Abstract #641.
`Neuwirtova, R. et al., “Immunomodulatory therapy of low-risk
`myelodysplastic syndromes,” Onkologie, 2000, 23(7):82 Abstract
`#0305.
`Partial European Search Report in corresponding EP Appl. No.
`048219877 dated Mar. 23, 2009.
`
`Aparicio et al., Current Opinion in Investigational Drugs, 2002, 3(4),
`627-33.
`Argeme et al., Journal of Pharmaceutical and Biomedical Analysis,
`2007,44, 859-66.
`Balaian et al., “5-Azacytidine Augrnents the Cytotoxicity of
`Mylotarg Toward AML Blasts In Vitro and In Vivo,” Blood, 2007,
`110(11), Part 1, 543A-544A (American Society of Hematology,
`Annual Meeting. Dec. 8-11, 2007, Abstract #1835).
`Beisler eta1., Journal of Medicinal Chemistry, 1977, 20(6), 806-12.
`Bellet et al., Cancer Chemotherapy Reports, Part I, 1974, 58(2),
`217—22.
`Bellet et al., Medical and Pediatric Oncology. 1978, 4, 11-15.
`Bhuyan et al., Cancer Research, 1972, 32, 398-407.
`Bhuyan et al., Cancer Research, 1973, 33, 888-94.
`Braulke et al., “FISH-Analyses of Circulating CD34+ Cells in MDS
`PatientsiA Suitable Method to Measure and Predict Response to
`5-Azacytidine,”Blood. 2007, 110(11), Part 1, 727A-728A (American
`Society of Hematology, Annual Meeting, Dec. 8-11, 2007, Abstract
`#2466).
`Brcistol, K. ct al., “Antitumor Activity of P-4055 (claidic acid-
`cytarabine) Compared to Cytarbine in Metastatic and s.c. Human
`Tumor Xenograft Models,” Cancer Research, 1999, 59(12):2944-
`2949.
`Brock et al., New England Journal of Medicine, 2008, 358(11),
`1 1 18-28.
`Chan et al., Journal ofPharmaceutical Sciences, 1979, 68(7), 807- 12.
`Christman, Oncogene, 2002, 21, 5483-95.
`Official Action dated Feb. 10, 2009 in JP Application No. 2004-
`545192. (English translation provided.)
`Cunningham et al., Cancer Chemotherapy Reports, Part 1, 1974,
`58(5), 677-81.
`Curt et al., Cancer Research, 1985, 45, 3359-63.
`Das et al., Molecular Cancer, 200